Business
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
- DAWNZERA demonstrated significant and sustained HAE attack rate reduction and long-term disease control - - Offers longest dosing option for HAE, with
About this update from Ionis Pharmaceuticals, Inc.
[{"type":"text","content":"\n- DAWNZERA demonstrated significant and sustained HAE attack rate reduction and long-term disease control -\n\n\n- Offers longest dosing option for HAE, with dosing every 4 or 8 weeks -\n\n\n- Compelling profile supported by recently published switch data -\n\n\n- Ionis’ second independent launch in just nine months, with potential for two additional launches next year -\n\n\n- Ionis to host webcast today at 12:15pm ET -\n\n\n CARLSBAD, Calif.--(BUSINESS WIRE)--\nIonis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. DAWNZERA is the first and only RNA-targeted medicine approved for HAE, designed to target plasma prekallikrein (PKK), a key protein that activates inflammatory mediators associated with acute attacks of HAE. DAWNZERA 80mg is self-administered via subcutaneous autoinjector once every four (Q4W) or eight weeks (Q8W).\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250818615141/en/DAWNZERA (donidalorsen) logo\nHAE is a rare and potentially life-threatening genetic condition that involves recurrent attacks of severe swelling (angioedema) in various parts of the body, including the hands, feet, genitals, stomach, face and/or throat. HAE is estimated to affect approximately 7,000 people in the U.S.\n\n\n“DAWNZERA represents a significant advance for people living with HAE who need improved treatment options. With strong and durable efficacy, convenient administration and the longest dosing option available, we believe DAWNZERA will be the prophylactic treatment of choice for many people living with HAE. Importantly, the recently published switch data empowers patients and physicians with a roadmap for switching to DAWNZERA from other prophylactic therapies,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “At Ionis, we are dedicated to turning groundbreaking science into life-changing medicines. With the early success of our first independent launch of TRYNGOLZA® for familial chylomicronemia syndrome (FCS), and now with DAWNZERA, our second independent medicine approved in less than nine months, we are proudly delivering on that visi...